CCT241161

CCT241161 Suppliers list
Company Name: HANGZHOU CLAP TECHNOLOGY CO.,LTD
Tel: 86-571-88216897,88216896 13588875226
Email: sales@hzclap.com
Products Intro: Product Name:CCT241161
CAS:1163719-91-2
Purity:99% Package:10kg 25kg 200 kilograms per barrel Remarks:good
Company Name: Shanghai Rechem science Co., Ltd.  
Tel: 21-31433387 15618786686
Email: sales@rechemscience.com
Products Intro: CAS:1163719-91-2
Purity:98% Package:1g;5g
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774
Email: sales@glpbio.cn
Products Intro: Product Name:CCT241161
CAS:1163719-91-2
Purity:>98% Package:1mg;10mg;50mg;100mg;
Company Name: Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd  
Tel: 15317229551
Email: 15151849396@163.com
Products Intro: Product Name:CCT241161
CAS:1163719-91-2
Purity:98% HPLC Package:1g
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Email: marketing@tsbiochem.com
Products Intro: Product Name:CCT241161;CCT241161
CAS:1163719-91-2
Purity:98.48% Package:100 mg;5 mg;50 mg
CCT241161 Basic information
Product Name:CCT241161
Synonyms:CCT241161;Urea, N-[4-[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-(methylthio)phenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]-;N-[4-[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-(methylthio)phenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]-urea;1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-methylsulfanyl-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea
CAS:1163719-91-2
MF:C28H27N7O3S
MW:541.62
EINECS:
Product Categories:
Mol File:1163719-91-2.mol
CCT241161 Structure
CCT241161 Chemical Properties
density 1.36±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO: Soluble
form A solid
pka8.47±0.20(Predicted)
Safety Information
MSDS Information
CCT241161 Usage And Synthesis
DescriptionCCT241161 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. CCT241161 blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEK?–ERK, in vitro and in vivo. CCT241161 also prevented growth of xenografts derived from patient tumours with acquired or intrinsic resistance to BRAF and MEK inhibitors. BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs.
CCT241161 Preparation Products And Raw materials
Tag:CCT241161(1163719-91-2) Related Product Information